Your Article Summary
See Latest ArticlesMerck Prices $4.25 Billion Debt Offering
Merck & Co., 06/23/09
Proceeds from the notes will be used for general corporate purposes and/or to fund a portion of the cash consideration of the proposed Schering-Plough merger. In addition, Merck may use all or a portion of the proceeds to fully fund the two funds established for qualifying claims pursuant to the company's Vioxx litigation settlement agreement, in which case the collateral previously pledged in connection with such funds will be returned to Merck.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK completes extension of strategic collaboration with Aspen
GlaxoSmithKline, 12/02/09
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09